Coordinated High Dose Interleukin-2 (Aldesleukin, Proleukin™) and Pembrolizumab (Anti-PD1, Keytruda™) for Therapy of Metastatic Kidney Cancer
Phase of Trial: Phase II
Latest Information Update: 28 Sep 2017
At a glance
- Drugs Aldesleukin (Primary) ; Pembrolizumab (Primary)
- Indications Renal cancer
- Focus Therapeutic Use
- 22 Sep 2017 Planned End Date changed from 31 Dec 2018 to 31 Dec 2019.
- 12 Apr 2017 Status changed from not yet recruiting to recruiting.
- 03 Apr 2017 Planned initiation date changed from 30 Apr 2017 to 30 Jun 2017.